NASDAQ:QNTM Quantum Biopharma (QNTM) Stock Price, News & Analysis $3.80 +0.57 (+17.65%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$3.83 +0.03 (+0.87%) As of 08/14/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Quantum Biopharma Stock (NASDAQ:QNTM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quantum Biopharma alerts:Sign Up Key Stats Today's Range$3.31▼$3.9550-Day Range$2.83▼$4.0552-Week Range$2.07▼$22.57Volume272,121 shsAverage Volume214,325 shsMarket Capitalization$24.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. Read More Quantum Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreQNTM MarketRank™: Quantum Biopharma scored higher than 9% of companies evaluated by MarketBeat, and ranked 877th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingQuantum Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageQuantum Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Quantum Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Quantum Biopharma is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quantum Biopharma is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuantum Biopharma has a P/B Ratio of 2.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.19% of the float of Quantum Biopharma has been sold short.Short Interest Ratio / Days to CoverQuantum Biopharma has a short interest ratio ("days to cover") of 3.47, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quantum Biopharma has recently decreased by 10.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuantum Biopharma does not currently pay a dividend.Dividend GrowthQuantum Biopharma does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.16 News SentimentQuantum Biopharma has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Quantum Biopharma this week, compared to 3 articles on an average week.Search Interest4 people have searched for QNTM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows10 people have added Quantum Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Quantum Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders8.53% of the stock of Quantum Biopharma is held by insiders.Percentage Held by Institutions1.24% of the stock of Quantum Biopharma is held by institutions.Read more about Quantum Biopharma's insider trading history. Receive QNTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quantum Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNTM Stock News HeadlinesQuantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical TrialAugust 14 at 7:00 AM | globenewswire.comQuantum BioPharma (QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple SclerosisAugust 13 at 7:22 PM | finance.yahoo.comBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwide. The analyst, who called the 2020 crash early, is working with a former NSA codebreaker and Pentagon insider on a new approach to AI stocks ahead of August 31. Investors like Stephen and Keith W. say the tools helped shape their portfolios, though results vary and are not typical.August 16 at 1:00 AM | TradeSmith (Ad)Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple SclerosisAugust 13 at 2:21 PM | markets.businessinsider.comQuantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 Multiple Sclerosis TrialAugust 11, 2026 | theglobeandmail.comQuantum BioPharma (QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2August 10, 2026 | finance.yahoo.comQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary ResultsAugust 3, 2026 | markets.businessinsider.comQuantum BioPharma (QNTM) Advances MS Imaging Study With Encouraging Preliminary ResultsAugust 3, 2026 | finance.yahoo.comSee More Headlines QNTM Stock Analysis - Frequently Asked Questions How have QNTM shares performed this year? Quantum Biopharma's stock was trading at $7.30 at the beginning of 2026. Since then, QNTM stock has decreased by 47.9% and is now trading at $3.80. How were Quantum Biopharma's earnings last quarter? Quantum Biopharma Ltd. (NASDAQ:QNTM) issued its quarterly earnings results on Thursday, August, 13th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.06. How do I buy shares of Quantum Biopharma? Shares of QNTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quantum Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quantum Biopharma investors own include Jiuzi (JZXN), Aethlon Medical (AEMD), Aditxt (ADTX), Adial Pharmaceuticals (ADIL), Avalon GloboCare (ALBT), Ainos (AIMD) and AMC Entertainment (AMC). Company Calendar Last Earnings8/13/2026Today8/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 QNTM's financial health is in the Yellow zone, according to TradeSmith. QNTM has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:QNTM Previous SymbolNASDAQ:QNTM CIK1771885 Webwww.fsdpharma.com Phone416-854-8884FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($5.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-674.48% Return on Assets-187.56% Debt Debt-to-Equity RatioN/A Current Ratio0.63 Quick Ratio0.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book2.84Miscellaneous Outstanding Shares6,399,000Free Float5,853,000Market Cap$24.32 million OptionableN/A Beta0.45 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:QNTM) was last updated on 8/16/2026 by MarketBeat.com Staff. From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...TradeSmith | SponsoredThis tiny launch company operates next to SpaceX and Blue OriginA small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...Freedom Financial | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quantum Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quantum Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
